Breaking News

Ligand Earns Milestone for Kyprolis Sales

By Kristin Brooks | February 11, 2014

Receives $1 million commercial milestone payment from Onyx

Ligand Pharmaceuticals, Inc. has earned $1 million commercial milestone payment from Onyx Pharmaceuticals, a subsidiary of Amgen, triggered by the achievement of more than $250 million of annual product sales of Kyprolis in 2013.
Ligand receives royalties for Kyprolis and is eligible to receive additional commercial and regulatory milestones. Kyprolis is indicated to treat multiple myeloma and was received accelerated approval from FDA in July 2012.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks